Related Experiment Videos
Summary of FDA antibody-mediated rejection workshop
P Archdeacon1, M Chan, C Neuland
1Division of Special Pathogen and Transplant Products, Office of Antimicrobial Products, Center for Drug Evaluation and Research, FDA, Silver Spring, MD, USA.
Summary
Antibody-mediated rejection (AMR) in kidney transplantation is a complex challenge. Experts convened to discuss antibody detection, clinical trial design, and treatment strategies for AMR, aiming to improve patient outcomes.
Area of Science:
- Nephrology and immunology, focusing on transplantation science.
- Clinical trial design and regulatory science.
Background:
- Antibody-mediated rejection (AMR) poses a significant threat to kidney transplant recipients.
- Current understanding and management of AMR require further scientific advancement.
Framework:
- Discussion centered on antibody detection, quantitation, and monitoring of donor-specific antibodies (DSAs).
- Consideration of desensitization protocols, acute AMR, and chronic AMR (CAMR) in clinical trial design.
- Exploration of the utility of animal models for studying AMR.
Implementation:
- Review of diagnostic and prognostic histological features, including sensitivity and specificity.
- Summary of existing literature on acute AMR treatments, highlighting case series and limited controlled trial data.
- Considerations for future clinical trials, including endpoint selection and statistical analysis.
Implications:
- The workshop facilitated critical exchange among experts on AMR in kidney transplantation.
- Identified key areas needing further research and development for improved AMR management.
- Aims to inform future clinical trial design and regulatory pathways for AMR therapies.
Related Concept Videos
00:42Cross-reactivity
Overview
01:30Drug Toxicity: Allergic Reactions
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.